BioStem Technologies, Inc. reports results for the quarter ended June 30 - Earnings Summary

BioStem Technologies

14/08/2026 01:35

BioStem Technologies, Inc. <> reported a quarterly adjusted loss of 52 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -3 cents.  The lone analyst forecast for the quarter was for a loss of 50 cents per share. 
Revenue fell 84% to $7.90 million from a year ago; analysts expected $6.35 million. 
BioStem Technologies, Inc.'s reported EPS for the quarter was a loss of 52 cents​.
The company reported a quarterly loss of $8.97 million.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for BioStem Technologies, Inc. is $7.00, about 55.7% above its last closing price of $3.10
This summary was machine generated from LSEG data August 14 at 12:35 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.50
-0.52
Missed
Mar. 31 2026 
-0.28
-0.52
Missed
Sep. 30 2025 
0.00
0.03
Beat